Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
QuantumLeap Healthcare Collaborative
Novartis
Kivu Bioscience Inc.
Bayer
University of California, Irvine
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Dana-Farber Cancer Institute
Washington University School of Medicine
Essen Biotech
Angiex, Inc.
MacroGenics
Avacta Life Sciences Ltd
Alliance for Clinical Trials in Oncology
University of Nebraska
Adela, Inc
Var2 Pharmaceuticals
Mayo Clinic
Tanabe Pharma America, Inc.
British Columbia Cancer Agency
Washington University School of Medicine
Travera Inc
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
University of California, Irvine
German Cancer Research Center
University Medical Center Groningen
University Health Network, Toronto
Institut du Cancer de Montpellier - Val d'Aurelle
Stanford University
BostonGene
Institut du Cancer de Montpellier - Val d'Aurelle
University of California, Davis
Zhejiang Provincial People's Hospital
Second Affiliated Hospital of Guangzhou Medical University